Journal ArticleDOI
The Role of Nano-ophthalmology in Treating Dry Eye Disease
Subramanian Natesan,Sai H.S. Boddu,Venkateshwaran Krishnaswami,Moyad Shahwan +3 more
- Vol. 8, Iss: 4, pp 258-289
Reads0
Chats0
TLDR
This review presents an overview, pathophysiology, prevalence and etiology of DED, with an emphasis on preclinical and clinical studies involving the use of nanocarrier systems in treating DED.Abstract:
Dry eye disease (DED) is a common multifactorial disease linked to the tears/ocular surface leading to eye discomfort, ocular surface damage, and visual disturbance. Antiinflammatory agents (steroids and cyclosporine A), hormonal therapy, antibiotics, nerve growth factors, essential fatty acids are used as treatment options of DED. Current therapies attempt to reduce the ocular discomfort by producing lubrication and stimulating gland/nerve(s) associated with tear production, without providing a permanent cure for dry eye. Nanocarrier systems show a great promise to revolutionize drug delivery in DED, offering many advantages such as site specific and sustained delivery of therapeutic agents. This review presents an overview, pathophysiology, prevalence and etiology of DED, with an emphasis on preclinical and clinical studies involving the use of nanocarrier systems in treating DED. Lay Summary: Dry eye disease (DED) is a multifactorial disease associated with tear deficiency or excessive tear evaporation. There are several review articles that summarize DED, disease symptoms, causes and treatment approaches. Nanocarrier systems show a great promise to revolutionize drug delivery in DED, offering many advantages such as site specific and sustained delivery of therapeutic agents. Very few review articles summarize the findings on the use of nanotherapeutics in DED. In this review, we have exclusively discussed the preclinical and clinical studies of nanotherapeutics in DED therapy. This information will be attractive to both academic and pharmaceutical industry researchers working in DED therapeutics.read more
Citations
More filters
Journal ArticleDOI
Anti-oxidative and mucin-compensating dual-functional nano eye drops for synergistic treatment of dry eye disease
TL;DR: Wang et al. as mentioned in this paper developed a synergistic nanoparticle (NP) that can treat dry eye disease by scavenging reactive oxygen species (ROS) and promoting mucin production.
Journal ArticleDOI
Small interfering RNAs based therapies for intracerebral hemorrhage: challenges and progress in drug delivery systems
Daniyah A. Almarghalani,Sai H.S. Boddu,Mohammad Ali,Akhila Kondaka,Devin Ta,R. Shah,Zahoor A. Shah +6 more
TL;DR: The obstacles to siRNA delivery are discussed, including the advantages and disadvantages of viral and nonviral vectors, and a comprehensive overview of recent progress in nanotherapeutics areas is provided, primarily focusing on the delivery system of siRNA for ICH treatment.
Journal ArticleDOI
The Therapeutic Benefits of Nanoencapsulation in Drug Delivery to the Anterior Segment of the Eye: A Systematic Review
TL;DR: The majority of the in vivo studies demonstrated some improvement after nanoencapsulation, but the duration of the benefit varied from less than 1 h to more than 20 h, and the most common in vitro methods performed in the studies were drug release, transcorneal permeation, and mucin interaction.
Book ChapterDOI
Combination drug delivery approaches in ophthalmology
TL;DR: A comprehensive overview of drug-device combinations that have reached the final preclinical and clinical stages for ocular diseases such as glaucoma, dry eye disease, infections, and inflammations can be found in this paper .
Journal ArticleDOI
Advances in In-vitro bioequivalence testing methods for complex ophthalmic generic products.
Jwala Renukuntla,Sushesh Srivatsa Palakurthi,Pradeep Kumar Bolla,Bradley A. Clark,Sai Hs Boddu,Prashanth Manda,Samuel Sockwell,Nitin Charbe,Srinath Palakurthi +8 more
TL;DR: In this article , the status of biorelevant in-vitro drug release testing (IVRT) approaches for complex ophthalmic products concerning the product-specific FDA guidance to the generic industry is reviewed.
References
More filters
Journal ArticleDOI
Nanocarriers as an emerging platform for cancer therapy
Dan Peer,Jeffrey M. Karp,Jeffrey M. Karp,Seungpyo Hong,Omid C. Farokhzad,Rimona Margalit,Robert Langer +6 more
TL;DR: The arsenal of nanocarriers and molecules available for selective tumour targeting, and the challenges in cancer treatment are detailed and emphasized.
Journal ArticleDOI
Block copolymer micelles for drug delivery: design, characterization and biological significance
TL;DR: The utility of polymeric micelles formed through the multimolecular assembly of block copolymers as novel core-shell typed colloidal carriers for drug and gene targeting and their feasibility as non-viral gene vectors is highlighted.
Journal ArticleDOI
Solid lipid nanoparticles: Production, characterization and applications
W. Mehnert,Karsten Mäder +1 more
TL;DR: An overview about the selection of the ingredients, different ways of SLN production and SLN applications, and the in vivo fate of the carrier are presented.
Journal ArticleDOI
Microemulsion-based media as novel drug delivery systems
M. Jayne Lawrence,Gareth D. Rees +1 more
TL;DR: The use of microemulsions and closely related microemulsion-based systems as drug delivery vehicles is reviewed, with particular emphasis being placed on recent developments and future directions.
Journal ArticleDOI
Structure and design of polymeric surfactant-based drug delivery systems.
TL;DR: The review concentrates on the use of polymeric micelles as pharmaceutical carriers and the basic mechanisms underlying micelle longevity and steric protection in vivo are considered with a special emphasis on long circulating drug delivery systems.